In the current AD diagnostic criteria, cerebrospinal fluid (CSF), namely, CSF amyloid_ 42 (A_ 42) or A_ 42/40, phosphorylated tau and total tau levels and PET biomarkers, that is, amyloid PET and tau PET, were often included. This evidence concerns the gene MAPT and Alzheimer disease.